Saving African American's diagnosed with COVID-19

A clinical study is underway of NOi's NOviricid, the FIRST Oral Systemic Nitric Oxide based COVID-19 Drug. This is the first and only COVID-19 study specifically addressing the health disparities in people of color,  one of the most affected, high-risk populations of the virus.

The COVID-19 pandemic has killed over half a million people. Despite the vaccine and its unknown side-effects, duration of efficacy, and effect on mutations, every year people will continue to contract the virus. While the vaccine hopes to prevent the virus, NOviricid seeks to save those infected with COVID-19 and all of its mutations.

Dr Nathan S. Bryan Ph.D.


  • The recognized expert and thought leader in nitric oxide

  • Innovative and prolific inventor

  • More than two dozen issued U.S. and International Patents on nitric oxide technology

  • Hundreds of peer-reviewed publications in the nitric oxide field

  • His patented technology is responsible for hundreds of millions of dollars in product sales worldwide

Nitric Oxide Based Therapeutics
for Human Disease





R & D

The Journey Towards Disease & Aging Prevention Begins with

Sufficient Nitric Oxide Production.

"The discovery of nitric oxide and its function is one of the most important in the history of cardiovascular medicine."

- Valentine Fuster, M.D.
1998 President, American Heart Association
Head of Cardiology, Mount Sinai Hospital NYC

The Healthy Feed